New ruthenium(II)/phosphines/diimines complexes: Promising antitumor (human breast cancer) and Mycobacterium tuberculosis fighting agents
Nenhuma Miniatura disponível
Data
2013-03-04
Autores
Dos Santos, Edjane R.
Mondelli, Melina A.
Pozzi, Lucas V.
Corrêa, Rodrigo S.
Salistre-De-Araújo, Heloisa S.
Pavan, Fernando Rogério [UNESP]
Leite, Clarice Q.F. [UNESP]
Ellena, Javier
Malta, Valéria R.S.
MacHado, Sérgio P.
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
The synthesis and characterization of ruthenium compounds of the type [RuCl2(P)2(N-N)] [(P)2 = (PPh3) 2, dppb = 1,4-bis(diphenylphosphino)butano; dppp = 1,3-bis(diphenylphosphino)propane; N-N = 5,5′-dimethyl-2,2′dipyridyl (5,5′-mebipy) or 4,4′-dimethyl-2,2′dipyridyl (4,4′-mebipy)] are described. The complexes were characterized using elemental analysis, UV-Vis and infrared spectroscopies, cyclic voltammetry, and X-ray crystallography. In vitro evaluation of the complexes, using the MTT methodology, revealed their cytotoxic activities in a range of 5.4-15.7 μM against the MDA-MB-231 breast tumor cells and showed that, in this case, they are more active than the reference metallodrug cisplatin. The in vitro antimycobacterial activities of the complexes had their Minimum Inhibitory Concentration (MIC) for MTB cell growth measured, by the REMA method. The MICs for these complexes were found to be between 12.5 and 25.0 μg/mL. The results are comparable with the second line drug cycloserine (MIC = 12.5-50.0 μg/mL), commonly used in the treatment of TB. © 2013 Elsevier Ltd. All rights reserved.
Descrição
Palavras-chave
Antimycobacterial activity, Cytotoxity, Phosphine/diimine complexes, Ruthenium(II) complexes
Como citar
Polyhedron, v. 51, n. 1, p. 292-297, 2013.